je.st
news
Tag: trial
TECOS, Mercks Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
2015-06-08 22:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings Published in the New England Journal of Medicine and Presented at the American Diabetes Association Scientific Sessions Treatment with Sitagliptin Did Not Increase the Risk of Major Adverse Cardiovascular Events in the Primary Composite Endpoint, or Hospitalization for Heart Failure, Compared with Placebo KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the cardiovascular (CV) safety of Mercks DPP-4 inhibitor, JANUVIA (sitagliptin), added to usual care in more than 14,000 patients. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Media Capsule: Please Activate Javascript !function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://s3.amazonaws.com/contentcapsule.com/clients/Merck/tags/d5542d85-2f26-45dc-b64c-3ee84a4312ff_reg_frame.js?dt="+dt;fjs.parentNode.insertBefore(js,fjs);}}(document,"script","contentcapsule-embed-d5542d85-2f26-45dc-b64c-3ee84a4312ff"); Ticker Slug: Ticker: MRK Exchange: NYSE read more
Deliberations near in ex-BP executive's oil spill trial
2015-06-05 00:41:42| Oil & Gas - Topix.net
Closing arguments have been scheduled in the case of David Rainey, the former BP executive charged with lying to federal investigators about the 2010 BP oil spill. Attorneys will make their final statements to jurors Friday morning and the jury is expected to begin deliberations by noon.
Tags: trial
oil
executives
spill
Japan's Energia in G.fast trial
2015-06-02 02:00:00| Total Telecom industry news
Electricity firm's communications business looks to boost network speeds to meet growing demand.
Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial ...
2015-06-01 20:27:17| Biotech - Topix.net
Apricus Biosciences, Inc. , a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has begun enrolling patients in a Phase 2b clinical trial to evaluate Apricus' novel product candidate, fispemifene, a selective estrogen receptor modulator , for the treatment of men with symptomatic secondary hypogonadism also known as low testosterone. The Phase 2 proof-of-concept clinical trial is a randomized, double-blind, placebo-controlled, parallel arm, multi-center study in approximately 160 hypogonadal men aged 18 to 64 who present with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone.
Tags: trial
phase
patients
clinical
Cavion to Present Clinical Trial Data at ASCO
2015-05-29 02:53:23| Logistics - Topix.net
Cavion LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors and neurologic diseases, announced today that Matthias Holdhoff, MD, PhD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins will present preliminary results from an ongoing multi-site National Cancer Institute Adult Brain Tumor Consortium and Cavion-sponsored Phase 1b clinical trial at the 2015 Annual Meeting of the American Society of Clinical Oncology on June 1. This dose escalation trial, which completed enrollment in November 2014, evaluates the safety and pharmacokinetics of Cavion's novel cancer drug mibefradil when sequentially administered with temozolomide in patients with recurrent high-grade glioma.
Tags: data
present
trial
clinical
Sites : [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] next »